Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Dow hits record highs & S&P 500 healthcare gains. Discover key stock movers, Trump-era pharma tariffs capped, & major healthcare earnings updates.

Days after it was announced that the cost of Mounjaro weight-loss jabs in the UK would treble in September, sales of Ozempic had surged by 600 per cent.